文献速递重症综合管理与镇静镇痛

大非心脏手术中全静脉麻醉与挥发性吸入麻醉的比较:一项随机临床试验

Total Intravenous vs Volatile Inhalational Anesthesia for Major Noncardiac Surgery: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论在≥50岁择期大非心脏手术患者中,TIVA与吸入麻醉相比未改善30天存活且在家天数。

这项在49家英国NHS医院开展的实用型、多中心、开放标签RCT纳入2508例≥50岁择期大非心脏手术患者,1:1随机接受丙泊酚TIVA或挥发性吸入麻醉维持。主要终点30天存活且在家天数两组相似(22.5 vs 22.4天;IRR 1.00;95%CI 0.99-1.02;90天存活且在家天数、30天/90天/6个月死亡率、第3天QoR-15评分及谵妄均无差异;TIVA组口渴、声嘶、恶心呕吐发生率较低,两组各有1例确切或可能术中知晓(均在TIVA组)。

要点

  • 90天存活且在家天数、30天/90天/6个月死亡率、第3天QoR-15评分、谵妄(4AT)均无组间差异。
  • TIVA组口渴、声嘶、恶心呕吐发生率较低;总体 major complications 12.4%,组间无显著差异。
  • 2例确切或可能术中知晓均发生在TIVA组(丙泊酚输注维持)。
  • 适用人群为≥50岁择期大非心脏手术患者,急诊/ICU场景及非择期手术不适用。

适用人群与场景

  • 排除人群、急诊/ICU/院前场景及非择期手术:原文未提及。

诊断标准与关键阈值

  • 谵妄评估采用第3天4 As Test(4AT),87.6%患者第3天无谵妄。
  • 主要终点为30天存活且在家天数;次要终点包括90天存活且在家天数、30天/90天/6个月死亡率、第3天QoR-15、第1天Bauer患者满意度问卷、术中知晓、30天内major postoperative complications。

处置流程与药物剂量

  • 第一步:全麻维持随机采用TIVA(丙泊酚输注)或挥发性吸入麻醉药;丙泊酚具体剂量、输注速率及吸入药种类/浓度原文未提及。
  • 第二步:其余围术期管理均由临床医生酌情决定(原文未给出具体方案)。
  • 两组均评估第1天患者满意度、第3天QoR-15与4AT、30天内major complications及术中知晓。

红旗征与不能漏的情况

  • 术中知晓:2例确切或可能病例均发生在TIVA组,需警惕TIVA维持期间的知晓风险。
  • 原文未给出其他红旗征或需立刻处理的情况。

研究设计与关键结果

  • 实用型、多中心、开放标签RCT,49家英国NHS医院,2508例随机(TIVA 1254例 vs 吸入麻醉1254例),平均年龄67岁(SD 8.9),55%男性。
  • 90天存活且在家天数、30天/90天/6个月死亡率、第3天QoR-15评分均无差异。
  • TIVA组口渴、声嘶、恶心呕吐发生率较低;第3天谵妄组间相似(87.6%无谵妄);总体major complications 12.4%,组间无显著差异。
  • 2例确切或可能术中知晓均发生在TIVA组。

证据类型、等级与局限

  • 证据类型:实用型、多中心、开放标签随机临床试验(RCT),注册号ISRCTN62903453。
  • 局限:开放标签设计;原文未提及其他局限。

对床旁实践的改变

  • 对于≥50岁择期大非心脏手术患者,选择TIVA或挥发性吸入麻醉不影响30天存活且在家天数、90天存活且在家天数、30天/90天/6个月死亡率、第3天恢复质量或谵妄发生率,可按临床情况个体化选择。
  • TIVA可能降低口渴、声嘶、恶心呕吐,但需注意TIVA组出现2例确切或可能术中知晓。
  • 不适用于急诊/ICU场景及非择期手术患者;原文未提供TIVA具体药物剂量方案,不能据此推导通用推荐剂量。

指南或共识出处

  • 原文未提及指南或共识出处;本文为JAMA发表的随机临床试验(ISRCTN62903453)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Older adults undergoing major noncardiac surgery experience substantial postoperative morbidity and health care use. The comparative effectiveness of total intravenous anesthesia (TIVA) vs volatile-based inhalational anesthesia on recovery and safety remains uncertain.

OBJECTIVES: To determine whether TIVA improves days alive and at home at 30 days compared with inhalational anesthesia and to evaluate differences in patient-centered outcomes and recovery.

DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, multicenter, open-label randomized clinical trial conducted in 49 UK National Health Service hospitals from January 2022 to April 2024 (final follow-up, October 2024) among patients aged 50 years or older scheduled for elective major noncardiac surgery.

INTERVENTIONS: Participants were randomized 1:1 to receive maintenance of general anesthesia with either TIVA (propofol infusion) (n = 1254) or volatile-based inhalational agents (n = 1254). All other perioperative care was at clinician discretion.

MAIN OUTCOMES AND MEASURES: The primary outcome was days alive and at home at 30 days. Secondary outcomes included days alive and at home at 90 days; mortality at 30 days, 90 days, and 6 months; Quality of Recovery-15 score at day 3; patient satisfaction (Bauer Patient Satisfaction Questionnaire) at day 1; delirium (4 As Test [4AT]) at day 3; unintentional awareness under anesthesia; and major postoperative complications within 30 days.

RESULTS: Among the 2508 randomized participants, the mean age was 67 (SD, 8.9) years, and 55% were male. Characteristics were balanced across randomized groups. Days alive and at home at 30 days were similar between groups (mean, 22.5 [SD, 6.8] days vs 22.4 [SD, 6.6] days for TIVA vs inhalational anesthesia, respectively; incidence rate ratio, 1.00; 95% CI, 0.99-1.02; adjusted P = .68). There were no differences in days alive and at home at 90 days; mortality at 30 days, 90 days, or 6 months; or Quality of Recovery-15 score at day 3. Lower rates of thirst, hoarseness, and nausea and vomiting were reported in the TIVA group. Levels of delirium were similar between groups, with the majority (87.6%) having no delirium at day 3. Major complications occurred in 12.4% of patients overall, with no significant between-group differences. Two cases of certain or probable unintentional awareness under anesthesia were reported, both in the TIVA group.

CONCLUSIONS AND RELEVANCE: Among older adults undergoing major noncardiac surgery, TIVA did not improve days alive and at home at 30 days compared with inhalational anesthesia.

TRIAL REGISTRATION: ISRCTN.org Identifier: ISRCTN62903453.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Jhanji S, Booth K, Hiller L, et al. Total Intravenous vs Volatile Inhalational Anesthesia for Major Noncardiac Surgery: A Randomized Clinical Trial. JAMA. 2026. PMID: 42584898. doi:10.1001/jama.2026.11065

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。